|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Lonza_Group
gptkb:Sofinnova_Ventures
gptkb:Nestlé_Holdings,_Inc.
|
|
gptkbp:acquisition
|
gptkb:Nestlé_Health_Science
|
|
gptkbp:business_model
|
biopharmaceuticals
|
|
gptkbp:ceo
|
gptkb:Dr._Jayson_Dallas
|
|
gptkbp:clinical_trial
|
Phase 1
Phase 2
pediatric and adult patients
randomized controlled trial
positive efficacy results
multiple sites in the US
Phase 3 trial for peanut allergy
improved tolerance to peanuts
peanut allergy treatment
|
|
gptkbp:collaborations
|
academic institutions
pharmaceutical companies
|
|
gptkbp:committee
|
experts in allergy
|
|
gptkbp:employees
|
approximately 100
|
|
gptkbp:focus
|
food allergy treatments
|
|
gptkbp:founded
|
gptkb:2011
|
|
gptkbp:founder
|
gptkb:Dr._Stephen_D._Miller
|
|
gptkbp:goal
|
desensitization to allergens
|
|
gptkbp:headquarters
|
gptkb:Brisbane,_California
|
|
gptkbp:healthcare
|
2020 for Palforzia
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Aimmune Therapeutics
|
|
gptkbp:indication
|
peanut allergy
|
|
gptkbp:investment
|
gptkb:New_Enterprise_Associates
gptkb:Bessemer_Venture_Partners
gptkb:Canaan_Partners
gptkb:Orbi_Med_Advisors
Venture capital firms
|
|
gptkbp:location
|
gptkb:United_States
|
|
gptkbp:market
|
2020 for Palforzia
food allergy market
|
|
gptkbp:marketing_strategy
|
expand product pipeline
direct-to-consumer marketing
|
|
gptkbp:packaging
|
capsules
|
|
gptkbp:partnership
|
gptkb:DBV_Technologies
food allergy advocacy groups
|
|
gptkbp:products
|
gptkb:Palforzia
oral immunotherapy
|
|
gptkbp:receives_funding_from
|
grants and investments
|
|
gptkbp:regulatory_compliance
|
gptkb:European_Medicines_Agency
New Drug Application (NDA)
|
|
gptkbp:research_areas
|
allergy
allergen immunotherapy
desensitization therapy
|
|
gptkbp:research_focus
|
gptkb:vaccine
|
|
gptkbp:revenue
|
$50 million (2020)
|
|
gptkbp:safety_features
|
well-tolerated
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:type
|
gptkb:Company
|
|
gptkbp:website
|
www.aimmune.com
|